The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.

Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.

More efficient internalisation and release – not bystander activity – are the focus for this private ADC player.

Rybrevant underwhelms in Mariposa, handing a possible advantage back to AstraZeneca’s Tagrisso.

AstraZeneca’s trial lives up to its billing, though the benefit might be subgroup-driven, and comes at the cost of toxicity.